AIM: To explore the key points of personalized treatment and medication monitoring by clinical pharmacists in the perioperative period of moyamoya disease patients with endometriosis. METHODS: This study showed a moyamoya disease patient with endometriosis who accepting dual antiplatelet therapy and how to adjust medication during the perioperative period. Besides, monitoring the use proton pump inhibitors in the perioperative period and the formulating a plan of DIE postoperative recurrence prevention are also our objectives. RESULTS: Through individualized assessment of the patient, a personalized medication adjustments for dual antiplatelet therapy was determined. Individualized perioperative proton pump inhibitor regimen and postoperative prevention plan for endometriosis recurrence were developed. CONCLUSION: The development of individualized medication regimens and medication monitoring is the breakthrough point for clinical pharmacists to carry out pharmaceutical services.